Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Revvity Health Sciences Inc. is currently managing 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 4 distinct art units, indicating a broad technological reach within the life sciences. The portfolio involves 5 distinct examiners, with each of the 5 pending office actions assigned to a different individual.
SHAFQAT, AMY JEANETTE is the busiest examiner, though they only hold 1 pending office action. Since each of the 5 distinct examiners manages exactly 1 of the 5 pending office actions, the workload is evenly spread. This distribution across 4 distinct art units requires the company to manage 5 separate prosecution tracks, each with its own examiner-specific nuances. SHAFQAT, AMY JEANETTE is one of the 5 distinct examiners involved.
The presence of 4 distinct art units indicates that the company's Biotechnology & Pharmaceuticals filings are being evaluated by multiple administrative groups. With 5 distinct examiners providing feedback, the company must be prepared for a variety of prosecution styles. This decentralized structure for the 5 pending office actions ensures that the portfolio's progress is not dependent on the review of any single individual.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (75%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHAFQAT, AMY JEANETTE | 1 | 52.0% | +55.3% |
| DAUNER, JOSEPH G | 1 | 56.9% | +35.2% |
| HOPPE, EMMA RUTH | 1 | 42.1% | +56.8% |
| BUCHANAN, BAILEY CHEYENNE | 1 | 42.9% | +57.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18208140 | METHODS FOR DETECTING MUTATIONS IN TARGET NUCLEIC ACIDS USING DUAL PROBES | DAUNER, JOSEPH G | 13d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18208140 | METHODS FOR DETECTING MUTATIONS IN TARGET NUCLEIC ACIDS USING DUAL PROBES | DAUNER, JOSEPH G | 13d |
| 18641547 | Systems and Methods for 3D Reconstruction of Anatomical Organs and Inclusions Using Short-Wave Infra | SHAFQAT, AMY JEANETTE | — |
| 17688062 | UNIVERSAL BLOCKING OLIGONUCLEOTIDES FOR REDUCED OFF-TARGET HYBRIDIZATION IN HYBRIDIZATION CAPTURE METHODS | HOPPE, EMMA RUTH | — |
| 17556209 | DETECTING A TARGET NUCLEIC ACID IN A BIOLOGICAL SAMPLE | BUCHANAN, BAILEY CHEYENNE | — |
| Art Unit | Apps |
|---|---|
| 1682 | 2 |
| 3798 | 1 |
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18641547 | Systems and Methods for 3D Reconstruction of Anatomical Organs and Inclusions Using Short-Wave Infra | SHAFQAT, AMY JEANETTE | 3798 | §103 | Final Rejection | — | Pending | Apr 22, 2024 |
| 18208140 | METHODS FOR DETECTING MUTATIONS IN TARGET NUCLEIC ACIDS USING DUAL PROBES | DAUNER, JOSEPH G | 1682 | §102§103§112 | Final Rejection | 13d | Pending | Jun 09, 2023 |
| 17688062 | UNIVERSAL BLOCKING OLIGONUCLEOTIDES FOR REDUCED OFF-TARGET HYBRIDIZATION IN HYBRIDIZATION CAPTURE METHODS | HOPPE, EMMA RUTH | 1683 | §103 | Non-Final OA | — | Pending | Mar 07, 2022 |
| 17556209 | DETECTING A TARGET NUCLEIC ACID IN A BIOLOGICAL SAMPLE | BUCHANAN, BAILEY CHEYENNE | 1682 | §103 | Non-Final OA | — | Pending | Dec 20, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial